These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33910336)

  • 1. In search of the optimal proteosome inhibitor. How, when and for whom?
    Engelhardt M; Bringhen S; Moreau P; Wäsch R; Waldschmidt J
    Haematologica; 2021 Oct; 106(10):2539-2541. PubMed ID: 33910336
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of proteasome inhibitors.
    Downey SL; Florea BI; Overkleeft HS; Kisselev AF
    Curr Protoc Immunol; 2015 Apr; 109():9.10.1-9.10.8. PubMed ID: 25845565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
    Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
    Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
    Ang E; Pavlos NJ; Rea SL; Qi M; Chai T; Walsh JP; Ratajczak T; Zheng MH; Xu J
    J Cell Physiol; 2009 Aug; 220(2):450-9. PubMed ID: 19365810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
    Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
    Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expression, purification of proteasome subunit PSMB1 and application in screening of possible proteasome inhibitors].
    Fan C; Feng L; Zhang D; Pan S; Liu X; Guo D; Fan J
    Sheng Wu Gong Cheng Xue Bao; 2012 Feb; 28(2):233-42. PubMed ID: 22667125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
    Tsukamoto S
    Chem Pharm Bull (Tokyo); 2016; 64(2):112-8. PubMed ID: 26833439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
    Carmony K; Lee W; Kim KB
    Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
    Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
    Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in proteasome inhibitor-based cancer therapies.
    Dou QP
    Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
    [No Abstract]   [Full Text] [Related]  

  • 11. [Proteasome and proteasome inhibitors].
    Meunier L; Stoebner PE; Marque M; Henry L; Bureau JP; Lavabre-Bertrand T
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):895-8. PubMed ID: 16327721
    [No Abstract]   [Full Text] [Related]  

  • 12. Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.
    Wang X
    Eur J Heart Fail; 2013 Jun; 15(6):597-8. PubMed ID: 23639782
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of novel proteasome inhibitors based on phthalazinone scaffold.
    Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle.
    Lim HS; Archer CT; Kodadek T
    J Am Chem Soc; 2007 Jun; 129(25):7750-1. PubMed ID: 17536803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
    Vlachostergios PJ; Voutsadakis IA; Papandreou CN
    Cell Biol Toxicol; 2013 Aug; 29(4):199-211. PubMed ID: 23733249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.
    Mitsiades CS
    Cancer Cell; 2016 May; 29(5):611-612. PubMed ID: 27165736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
    Zhang C; Zhu H; Shao J; He R; Xi J; Zhuang R; Zhang J
    Future Med Chem; 2020 Feb; 12(4):269-272. PubMed ID: 31983229
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of proteasome inhibition in nonsmall cell lung cancer.
    Escobar M; Velez M; Belalcazar A; Santos ES; Raez LE
    J Biomed Biotechnol; 2011; 2011():806506. PubMed ID: 21629760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome Inhibitor Drugs.
    Fricker LD
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.